MHRA and eBay Partnership Shows Why Online Medicine Routes Need Strong Controls
The MHRA has announced that its ongoing partnership with eBay has removed a further 215 listings of potentially dangerous unauthorised erectile dysfunction medicines from the platform.
The regulator explained that unauthorised medicines sit outside MHRA oversight, meaning their contents are unknown. They may contain no active ingredient, too much active ingredient, or toxic ingredients.
The MHRA also said a cutting-edge AI algorithm developed with eBay blocked more than two million policy violations relating to prescription-only and non-prescription medicines in 2025 before products could be offered for sale to the public.
For the public, this is a clear warning about buying medicines through unsafe online routes.
For businesses, it is a reminder that the route matters.
What Happened and Why It Matters
The MHRA and eBay partnership is designed to remove unauthorised products from online sale and help protect public health.
According to the MHRA, erectile dysfunction medicines remain among the most frequently illegally traded medicines in the UK. The regulator also reminded the public that these medicines can only be dispensed through a UK registered pharmacy.
This matters because medicines are not ordinary online products.
They must move through appropriate, controlled and lawful channels.
If a product appears online without the right controls, several questions arise immediately:
- Is the product genuine?
- Is the seller authorised?
- Is the customer route appropriate?
- Is the product being supplied lawfully?
- Can the product be traced?
- Can the quality and safety position be trusted?
For medicines-related businesses, those questions are not theoretical. They are practical compliance questions.
What This Means for Businesses
Many businesses think about medicines wholesale in terms of products and commercial opportunity.
But regulated activity is not only about what is being supplied.
It is also about how it is supplied, who supplies it, who receives it and whether the route is suitable.
This is especially important where a business is:
- Exploring medicines wholesale
- Reviewing a new customer route
- Considering online or distance-selling models
- Working with third-party platforms
- Adding new suppliers
- Entering specialist medicines distribution
- Preparing for a WDA(H)
- Reviewing GDP readiness
The official MHRA guidance explains that anyone selling or supplying human medicines to anyone other than the patient must have a wholesale distribution licence, and to qualify for this licence, businesses must comply with GDP and pass regular GDP inspections.
That means a business must be able to show control, not just intent.
Why Online Routes Need Extra Care
Online channels can make selling easier, faster and more visible.
But they can also increase risk if the business does not control the route properly.
Risks may include:
- Unclear seller identity
- Weak customer qualification
- Unverified product origin
- Poor documentation
- Unsuitable supply to the public
- Lack of traceability
- Misunderstanding pharmacy, wholesale or distribution boundaries
- Products moving through channels not designed for regulated medicines
This is why a compliance route review is so important before online routes, marketplace models or distribution changes are pursued.
The question is not only “can this be sold?”
The better question is:
“Can this be supplied through this route lawfully, safely and with the right controls?”
What Businesses Should Check Now
If your business is involved in medicines wholesale, specialist distribution, WDA(H) readiness or online route planning, this news should prompt a review.
Start with these checks:
- Review whether your activity is clearly defined.
- Check whether the route involves wholesale supply, direct supply, brokerage, pharmacy activity or another regulated model.
- Review whether your suppliers are properly checked and documented.
- Check whether customers are suitable and appropriately qualified.
- Review whether online or marketplace activity creates extra risk.
- Check whether the Responsible Person has enough visibility.
- Review SOPs for customer approval, supplier approval, order processing and escalation.
- Check whether records are strong enough to evidence what happened.
- Review whether your current activity still matches your authorisation position.
A business should not wait until a problem appears before asking these questions.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support.
This may include:
- Compliance route reviews
- Supplier and customer qualification review
- GDP audit and readiness support
- Responsible Person / GDP quality support
- WDA(H) application readiness
- Ongoing compliance support
- Specialist medicines wholesale/distribution planning
Our role is to help businesses understand whether their route, systems and controls are strong enough before they move forward.
We help clients see what is missing, what needs strengthening and what should happen next.
Final Thought
The MHRA and eBay story is not only about illegal online medicine listings.
It is also about route control.
In medicines-related activity, the route, the parties, the records and the controls all matter.
A good opportunity can become a serious risk if the supply route is not properly understood.
Before moving forward, businesses should ask one simple question:
- Can we evidence, control and defend the route we are using
Need clarity on your online route, customer qualification or medicines wholesale compliance position?
Book a confidential consultation with Stag Global to review your route before risk becomes a problem.
